Authors
Ahmed Abdelsamad, Essa Alghunaim, Mahmoud Mokhtar, Hossam Zaglouol, Essam Sabry, Talal Al Saeed, Reem Alhajri, Nusaiba Alrefae, Kaushik Majumdar, Tahani AlBaqer, Amir A Ahmed, Dherar Alshehab, Adel Ayed, Mohammad I Ghanbar, Sulaiman Khadadah
Published in
Journal of bronchology & interventional pulmonology. Volume 33. Issue 4. Oct 01, 2026. Epub Sep 03, 2026.
Abstract
Real-world data examining structured modality selection for mediastinal/hilar adenopathy in mixed malignant and benign cohorts is limited. We evaluated the performance of a multidisciplinary team (MDT)-guided strategy incorporating EBUS/EUS-B and EUS for both benign and malignant disease.
We conducted a retrospective study, including consecutive adults undergoing mediastinal/hilar lymph node sampling by endoscopy after MDT discussion. All cases were discussed at a dedicated thoracic MDT before the procedure, where the indication for sampling and the modality were predetermined based on anatomic accessibility on CT/PET-CT, clinical data, and anticipated tissue requirements. The primary outcome was diagnostic yield, defined as the proportion of procedures providing a definitive pathologic diagnosis consistent with the clinical and radiologic context, with concordance for benign diagnoses confirmed by a minimum of 3 months of clinical and radiologic follow-up. Secondary outcomes included yield by indication, modality, and adequacy of molecular testing.
Among 213 patients (64.3% male; mean age 56±14.5 y), the overall diagnostic yield was 92%. Indications for biopsy comprised 134 suspected carcinomas and 79 suspected benign or lymphoproliferative cases. Diagnostic yield was 91.8% (n=123/134) in suspected carcinoma and 92.4% (n=73/79) in suspected benign or lymphoproliferative disease. Molecular testing was processed in 57 malignant cases, with 89.5% successful completion.
A structured, MDT-driven endosonographic strategy was associated with high diagnostic and molecular adequacy in this cohort of malignant and benign mediastinal/hilar lymphadenopathy. Given the nonrandomized design and small sample size, findings should be interpreted cautiously. Prospective studies are warranted to further define the optimal role of each modality.
PMID:
42687840
Bibliographic data and abstract were imported from PubMed on 03 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0